PRESS RELEASE published on 08/06/2024 at 09:00, 1 year 8 months ago Biotest increases sales in the first half of 2024 by 35% to Euro 372 million Biotest AG reports 35% sales increase to Euro 372 million in H1 2024. EBIT reaches Euro 78.4 million. FDA approves Yimmugo® and BNL facility. Positive revenue and earnings growth Revenue Growth FDA Approval Sales Increase Biotest AG H1 2024
PRESS RELEASE published on 08/06/2024 at 09:00, 1 year 8 months ago Northern Data Group announces Q2 Results, reaffirms 2024 guidance Northern Data Group reports Q2 revenue growth of 22% year-on-year to EUR 26 million, reaffirms 2024 revenue target of EUR 200-240 million, driven by Cloud and HPC infrastructure expansion Revenue Growth Northern Data Group 2024 Guidance Q2 Results HPC Solutions
PRESS RELEASE published on 08/06/2024 at 08:31, 1 year 8 months ago Cherry SE Releases 2024 Half-Year Report Cherry SE releases its 2024 Half-Year Report, showing revenue growth in DIGITAL HEALTH & SOLUTIONS segment and confirmed forecasts for 2024 Revenue Growth Cherry SE Forecasts 2024 Half-Year Report DIGITAL HEALTH & SOLUTIONS
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT, confirmant son avancement vers l'objectif de recrutement complet au premier trimestre 2025 Abivax Recrutement Essai Clinique Phase 3 ABTECT
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT, confirmant l'évolution favorable du projet. La société réaffirme ses prévisions pour 2025 Abivax Recrutement Traitement Phase 3 ABTECT
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Abivax announces ABTECT Phase 3 Trial surpasses 600-patient enrollment milestone, on track for full enrollment by early Q1 2025. Trial trends align with previous observations Abivax Obefazimod Ulcerative Colitis ABTECT Phase 3 Trial Enrollment Milestone
REGULATED PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Cie du Bois Sauvage: Terugkoop van eigen aandelen – Week van 29/07/2024 tot 02/08/2024 Cie du Bois Sauvage voert terugkoop van eigen aandelen uit zoals gemachtigd door de buitengewone algemene vergadering van 28 april 2021 NYSE Euronext Brussel Financiële Informatie Cie Du Bois Sauvage Terugkoop Eigen Aandelen Buitengewone Algemene Vergadering
REGULATED PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Cie du Bois Sauvage : Rachat d’actions propres – semaine du 29/07/2024 au 02/08/2024 La Compagnie du Bois Sauvage annonce le rachat de 655 actions propres sur le marché réglementé NYSE Euronext Bruxelles, conformément à l'autorisation de l'AG du 28/04/2021 Rachat D'actions NYSE Euronext Bruxelles Compagnie Du Bois Sauvage Transactions Actions Propres Autorisation AG
REGULATED PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Cie du Bois Sauvage: Buy back of own shares – week from 29/07/2024 to 02/08/2024 Compagnie du Bois Sauvage announces buy back of own shares from 29/07/2024 to 02/08/2024, totaling €179,277.00. Details available on www.bois-sauvage.be NYSE Euronext Market Brussels Financial Transactions Own Shares Compagnie Du Bois Sauvage Buy Back
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago VALNEVA - Declaration of shares and voting rights: July 31, 2024 VALNEVA declared changes in shares and voting rights including sale, transfer, and granting of double voting rights on various dates Voting Rights Shares Sale Transfer Valneva
Published on 04/22/2026 at 01:55, 10 hours 7 minutes ago Immutable Holdings Announces Director Resignation
Published on 04/22/2026 at 01:30, 10 hours 32 minutes ago Challenger West Assays Return Grades up to 60g/t Au
Published on 04/22/2026 at 00:00, 12 hours 2 minutes ago Zimtu Capital Corp. and Global Energy Metals Corporation Agree to Terminate Option Agreement for the Monument Peak Copper-Silver Project, Idaho
Published on 04/22/2026 at 00:00, 12 hours 2 minutes ago Grande Portage Resources Announces SEDAR+ Filing of Preliminary Economic Assessment (PEA) Study for the New Amalga Gold Project in SE Alaska
Published on 04/22/2026 at 11:36, 25 minutes ago Original-Research: Cabka NV (von First Berlin Equity Research GmbH): Kaufen
Published on 04/22/2026 at 11:35, 27 minutes ago Zendure Debuts SolarFlow Mix Series Across Europe -- Three Home Storage Systems, One Platform, Up to 91% Off the Bill
Published on 04/22/2026 at 11:30, 32 minutes ago Notification on the increase of the share capital of Eleving Group
Published on 04/22/2026 at 10:32, 1 hour 30 minutes ago EQS-Adhoc: K+S Aktiengesellschaft: EBITDA and adjusted free cash flow in the first quarter of 2026 significantly above market expectations; EBITDA forecast for the full year 2026 raised
Published on 04/22/2026 at 10:18, 1 hour 44 minutes ago Successful Listing on the Primary Market of Düsseldorf Stock Exchange Strengthens Capital Market Position and Growth Strategy
Published on 04/22/2026 at 07:00, 5 hours 2 minutes ago Chiffre d'affaires 1er trimestre 2026. 229,5M€ à devises constantes. 215,5 M€ à devises courantes.
Published on 04/22/2026 at 07:00, 5 hours 2 minutes ago Q1 2026 sales. €229.5m at constant exchange rates. €215.5m at current exchanges rates
Published on 04/21/2026 at 19:15, 16 hours 47 minutes ago AXA - Description of the Company’s share repurchase program
